Clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease

Abstract

Objective To observe the clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease. Methods A total of 75 CPHD patients admitted to Henan Provincial People's Hospital from August of 2016 to December of 2017 were randomly divided into the control group (37 cases) and the study group (38 cases). The control group received routine treatment, and the study group received tongxinluo capsule as an assistant treatment on the basis of routine treatment. Total therapeutic efficiency of the two groups was calculated, and LVEF, CO and ET-1, NO levels were compared before and after treatment. Results The total effective rate of the study group (94.73%) was higher than that of the control group (78.38%), and the difference was statistically significant (P<0.05). The levels of LVEF and CO in the study group were lower than those in the control group (P<0.05). The level of ET-1 in the study group was lower than that in the control group, and the level of NO in the study group was higher than that in the control group (P<0.05). Conclusion Tongxinluo capsule has a good clinical effect in the adjuvant treatment of CPHD. It can effectively improve the cardiac function and vascular endothelial function of patients, and can be widely used in clinical practice. Key words: Chronic pulmonary heart disease; Tongxinluo capsule; Cardiac function; Vascular endothelial function